Our Partners > Platinum Sponsors 2017
Founded in 1995, Acorda is focused on developing therapies to restore neurological function to people living with nervous system disorders. Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including multiple sclerosis, Parkinson’s disease, and migraine. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. Please visit www.acorda.com, our Facebook and LinkedIn pages, and follow @acordanews on Twitter to learn more. We also sponsor The Many Faces of OFF Facebook page; visit here.
Neurodegeneration strikes when we least expect it. Prime of life neurodegeneration is a spectrum of relatively rare diseases that often afflict people during productive, active years and lead to debilitating symptoms and early death. They are generally categorized as frontotemporal disorders and are characterized by progressive personality, behavior, language and motor decline. These diseases create a level of functional impairment that significantly compromises the ability to carry out activities of daily living. There is currently no treatment and no cure, but there is hope. Research into these diseases may be a gateway to understanding and ultimately preventing neurodegeneration.
CurePSP is the leading organization within this disease spectrum, providing support for patients, families and caregivers; awareness and education to healthcare professionals; and global research funding. Current research into prime of life diseases, especially progressive supranuclear palsy (PSP), is showing great promise for unlocking the secrets of neurodegeneration. To learn more, visit us at www.psp.org.
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
LSVT Global has researched and developed highly effective speech, physical and occupational therapy programs (LSVT LOUD and LSVT BIG) for people with Parkinson's disease. Visit our website to find LSVT Certified Clinicians near you, exercise videos for improving voice and movements, free online and live educational events, and a speech exercise software program. LSVT Global has trained over 30,000 clinicians from 73 countries. LSVT LOUD is the gold standard in speech treatment for people with PD, backed by 20+ years of funded research from the National Institutes of Health. LSVT LOUD can now be received in person or via telehealth (eLOUD) or by using our LSVT Companion speech exercise program. The LSVT BIG physical/occupational therapy program empowers people with PD to improve their movement and balance for greater confidence at work, home, and play. During the Unity Walk, meet LSVT LOUD and LSVT BIG experts at our booth and learn more about how you can keep your voice and movements alive! For more information, visit www.LSVTGlobal.com.
Deep brain stimulation (DBS) development started in 1987 and Medtronic has been the leader in the field ever since, with over 140,000 implanted with Medtronic DBS Therapy. The Medtronic DBS Therapy system has been rigorously tested with clinical evidence and is FDA approved for people with Parkinson’s who had recent onset of movement symptoms as well as those with longer-standing movement symptoms. To learn more about Medtronic DBS Therapy, please visit www.MedtronicDBS.com.
As a global leader in medical technology, services and solutions, Medtronic strives to improve the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations and the burden of chronic disease — faced by families and healthcare systems today. But no one can do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes. Join us in our commitment to take healthcare Further, Together.
Many advanced Parkinson’s disease patients suffer motor complications that cannot be adequately controlled with current therapies. NeuroDerm is working to provide advanced stage patients with a new therapeutic option that offers a safe, simple and effective alternative to current highly invasive treatment alternatives that involve surgery. NeuroDerm has pioneered a liquid form of levodopa, a proven mainstay of Parkinson’s disease treatment. In clinical trials, NeuroDerm has enabled - for the first time - continuous subcutaneous administration of this drug. The treatments being developed by NeuroDerm are intended to make a meaningful difference in the quality of patients’ and their families’ lives.
Continuous Therapy – Because Life Goes ON.
Please visit our booth at the Parkinson's Unity Walk on April 22nd 2017 and go to www.neuroderm.com for more information.
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world — in nutrition, diagnostics, medical devices and branded generic pharmaceuticals — that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
Click for a printer friendly version